Advertisement

Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada

Published:November 03, 2016DOI:https://doi.org/10.1016/j.jhep.2016.10.028

      Background & Aims

      Evidence is limited on hepatocellular carcinoma (HCC) risk after sustained virological response (SVR) to interferon-based treatment of hepatitis C virus (HCV) infection. We evaluated the effect of SVR on the risk of HCC and estimated its incidence in post-SVR HCV patients from a large population-based Canadian cohort.

      Methods

      The British Columbia Hepatitis Testers Cohort includes individuals tested for HCV between 1990–2013 linked with data on their medical visits, hospitalizations, cancers, prescription drugs and mortality. Patients receiving interferon-based HCV treatments were followed from the end of treatment to HCC diagnosis, death or December 31, 2012. We examined HCC risk among those who did and did not achieve SVR using multivariable proportional hazard models with the Fine and Gray modification for competing risks.

      Results

      Of 8147 individuals who received HCV treatment and were eligible for analysis, 4663 (57%) achieved SVR and 3484 (43%) did not. Each group was followed for a median of 5.6 years (range: 0.5–12.9) for an HCC incidence rate of 1.1/1000 person-years (PY) among the SVR and 7.2/1000 PY among the no SVR group. The HCC incidence rate was higher among those with cirrhosis (SVR: 6.4, no SVR: 21.0/1000 PY). In the multivariable model, SVR was associated with a lower HCC risk (subdistribution hazard ratio [SHR] = 0.20, 95% CI: 0.13–0.3), while cirrhosis (SHR = 2.61, 95% CI: 1.68–4.04), age ⩾50 years, being male and genotype 3 infection were associated with a higher HCC risk. Among those who achieved SVR, cirrhosis, age ⩾50 years and being male were associated with a higher HCC risk.

      Conclusion

      SVR after interferon-based treatment substantially reduces but does not eliminate HCC risk, which is markedly higher among those with cirrhosis and age ⩾50 years at treatment initiation. Treatment of patients at an advanced fibrosis stage with new highly effective drugs will warrant continued surveillance for HCC post-SVR.

      Lay summary

      We assessed the effect of successful hepatitis C treatment with older interferon-based treatment on the occurrence of liver cancer (hepatocellular carcinoma) and found that successful treatment prevents liver cancer. However, more people with cirrhosis and older age continued to develop liver cancer after successful treatment. Thus, treatment with new drugs among those with cirrhosis will require continued monitoring for liver cancer.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Mohd Hanafiah K.
        • Groeger J.
        • Flaxman A.D.
        • Wiersma S.T.
        Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.
        Hepatology. 2013; 57: 1333-1342
        • Janjua N.Z.
        • Yu A.
        • Kuo M.
        • Alvarez M.
        • Cook D.
        • Wong J.
        • et al.
        Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort.
        BMC Infect Dis. 2016; 16: 334
        • Smith B.D.
        • Morgan R.L.
        • Beckett G.A.
        • Falck-Ytter Y.
        • Holtzman D.
        • Ward J.W.
        Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention.
        Ann Intern Med. 2012; 157: 817-822
        • Beste L.A.
        • Leipertz S.L.
        • Green P.K.
        • Dominitz J.A.
        • Ross D.
        • Ioannou G.N.
        Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013.
        Gastroenterology. 2015; 149 ([quiz e1417–e1478]): 1471-1482e1475
        • Chou R.
        • Hartung D.
        • Rahman B.
        • Wasson N.
        • Cottrell E.B.
        • Fu R.
        Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.
        Ann Intern Med. 2013; 158: 114-123
        • Janjua N.Z.
        • Kuo M.
        • Yu A.
        • Alvarez M.
        • Wong S.
        • Cook D.
        • et al.
        The population level cascade of care for hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
        EBioMedicine. 2016; 12: 189-195
        • Krajden M.
        • Yu A.
        • Cook D.
        • Kuo M.
        • Alvarez M.
        • Tyndall M.
        • et al.
        Hepatitis C virus (HCV) mortality patterns in the British Columbia Hepatitis Testers Cohort (BC-HTC).
        Hepatology. 2015; 62: 252A
        • Myers R.P.
        • Krajden M.
        • Bilodeau M.
        • Kaita K.
        • Marotta P.
        • Peltekian K.
        • et al.
        Burden of disease and cost of chronic hepatitis C infection in Canada.
        Can J Gastroenterol Hepatol. 2014; 28: 243-250
        • Krajden M.
        • Kuo M.
        • Zagorski B.
        • Alvarez M.
        • Yu A.
        • Krahn M.
        Health care costs associated with hepatitis C: a longitudinal cohort study.
        Can J Gastroenterol. 2010; 24: 717-726
        • Ly K.N.
        • Hughes E.M.
        • Jiles R.B.
        • Holmberg S.D.
        Rising mortality associated with hepatitis C virus in the United States, 2003–2013.
        Clin Infect Dis. 2016; 62: 1287-1288
        • Bruix J.
        • Sherman M.
        American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update.
        Hepatology. 2011; 53: 1020-1022
        • D’Ambrosio R.
        • Colombo M.
        Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?.
        Liver Int. 2016; 36: 783-790
        • Morgan R.L.
        • Baack B.
        • Smith B.D.
        • Yartel A.
        • Pitasi M.
        • Falck-Ytter Y.
        Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.
        Ann Intern Med. 2013; 158: 329-337
        • Li D.K.
        • Chung R.T.
        Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.
        Cancer. 2015; 121: 2874-2882
        • Di Marco V.
        • Calvaruso V.
        • Ferraro D.
        • Bavetta M.G.
        • Cabibbo G.
        • Conte E.
        • et al.
        Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension.
        Gastroenterology. 2016; 151: 130-139e132
        • Rutter K.
        • Stattermayer A.F.
        • Beinhardt S.
        • Scherzer T.M.
        • Steindl-Munda P.
        • Trauner M.
        • et al.
        Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.
        Aliment Pharmacol Ther. 2015; 41: 521-531
        • Pinzani M.
        Liver fibrosis in the post-HCV Era.
        Semin Liver Dis. 2015; 35: 157-165
        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • Eser S.
        • Mathers C.
        • Rebelo M.
        • et al.
        Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012.
        Int J Cancer. 2015; 136: E359-E386
        • El-Serag H.B.
        • Kanwal F.
        • Richardson P.
        • Kramer J.
        Risk of hepatocellular carcinoma after sustained virologic response in veterans with HCV-infection.
        Hepatology. 2016; 64: 130-137
      1. BC Cancer Agency [creator]. BC Cancer Agency Registry Data.
        BC Cancer Agency, 2013
      2. British Columbia Ministry of Health [creator]. PharmaNet.
        Victoria British Columbia Ministry of Health, 2013
      3. British Columbia Ministry of Health [creator]. Medical Services Plan (MSP) Payment Information File.
        Victoria British Columbia Ministry of Health, 2013
      4. British Columbia Ministry of Health [creator]. Discharge Abstract Database (Hospital Separations).
        Victoria British Columbia Ministry of Health, 2013
      5. BC Vital Statistics Agency [creator]. Vital Statistics Deaths.
        Victoria BC Vital Statistics Agency, 2014
      6. British Columbia Ministry of Health [creator]. Client Roster (Client Registry System/Enterprise Master Patient Index). 2013 [Available from: http://www.health.gov.bc.ca/data/.

        • Janjua N.Z.
        • Kuo M.
        • Chong M.
        • Yu A.
        • Alvarez M.
        • Cook D.
        • et al.
        Assessing hepatitis C burden and treatment effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design and characteristics of linked and unlinked participants.
        PLoS One. 2016; 11e0150176
        • Myers R.P.
        • Ramji A.
        • Bilodeau M.
        • Wong S.
        • Feld J.J.
        An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.
        Can J Gastroenterol. 2012; 26: 359-375
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • Fong A.
        • Burnand B.
        • Luthi J.C.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Fine J.P.
        • Gray R.J.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509
        • Singal A.G.
        • Pillai A.
        • Tiro J.
        Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.
        PLoS Med. 2014; 11e1001624
        • Padhya K.T.
        • Marrero J.A.
        • Singal A.G.
        Recent advances in the treatment of hepatocellular carcinoma.
        Curr Opin Gastroenterol. 2013; 29: 285-292
        • Aleman S.
        • Rahbin N.
        • Weiland O.
        • Davidsdottir L.
        • Hedenstierna M.
        • Rose N.
        • et al.
        A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
        Clin Infect Dis. 2013; 57: 230-236
        • Moon C.
        • Jung K.S.
        • Kimdo Y.
        • Baatarkhuu O.
        • Park J.Y.
        • Kim B.K.
        • et al.
        Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
        Dig Dis Sci. 2015; 60: 573-581
        • Ikeda M.
        • Fujiyama S.
        • Tanaka M.
        • Sata M.
        • Ide T.
        • Yatsuhashi H.
        • et al.
        Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
        J Gastroenterol. 2005; 40: 148-156
        • Yamashita N.
        • Ohho A.
        • Yamasaki A.
        • Kurokawa M.
        • Kotoh K.
        • Kajiwara E.
        Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes.
        J Gastroenterol. 2014; 49: 1504-1513
        • Messori A.
        • Badiani B.
        • Trippoli S.
        Achieving sustained virological response in hepatitis C reduces the long-term risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures.
        Clin Drug Invest. 2015; 35: 843-850
        • Arase Y.
        • Kobayashi M.
        • Suzuki F.
        • Suzuki Y.
        • Kawamura Y.
        • Akuta N.
        • et al.
        Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
        Hepatology. 2013; 57: 964-973
        • Iwasaki Y.
        • Takaguchi K.
        • Ikeda H.
        • Makino Y.
        • Araki Y.
        • Ando M.
        • et al.
        Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.
        Liver Int. 2004; 24: 603-610
        • Kanwal F.
        • Kramer J.R.
        • Ilyas J.
        • Duan Z.
        • El-Serag H.B.
        HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.
        Hepatology. 2014; 60: 98-105
        • Lu M.
        • Li J.
        • Rupp L.B.
        • Holmberg S.D.
        • Moorman A.C.
        • Spradling P.R.
        • et al.
        Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.
        J Viral Hepat. 2016; 23: 718-729
        • Chang K.C.
        • Wu Y.Y.
        • Hung C.H.
        • Lu S.N.
        • Lee C.M.
        • Chiu K.W.
        • et al.
        Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.
        Br J Cancer. 2013; 109: 2481-2488
        • Nagaoki Y.
        • Aikata H.
        • Nakano N.
        • Shinohara F.
        • Nakamura Y.
        • Hatooka M.
        • et al.
        Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
        J Gastroenterol Hepatol. 2016; 31: 1009-1015
        • Denniston M.M.
        • Jiles R.B.
        • Drobeniuc J.
        • Klevens R.M.
        • Ward J.W.
        • McQuillan G.M.
        • et al.
        Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.
        Ann Intern Med. 2014; 160: 293-300
        • Dyal H.K.
        • Aguilar M.
        • Bartos G.
        • Holt E.W.
        • Bhuket T.
        • Liu B.
        • et al.
        Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review.
        Dig Dis Sci. 2016; 61: 636-645
        • Huang Y.W.
        • Wang T.C.
        • Yang S.S.
        • Lin S.Y.
        • Fu S.C.
        • Hu J.T.
        • et al.
        Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study.
        Aliment Pharmacol Ther. 2015; 42: 902-911
        • Toyoda H.
        • Kumada T.
        • Tada T.
        • Kiriyama S.
        • Tanikawa M.
        • Hisanaga Y.
        • et al.
        Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
        J Gastroenterol Hepatol. 2015; 30: 1183-1189
        • Reig M.
        • Marino Z.
        • Perello C.
        • Inarrairaegui M.
        • Ribeiro A.
        • Lens S.
        • et al.
        Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
        J Hepatol. 2016; 65: 719-726
        • Nault J.C.
        • Colombo M.
        Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
        J Hepatol. 2016; 65: 663-665
        • Kozbial K.
        • Moser S.
        • Schwarzer R.
        • Laferl H.
        • Al-Zoairy R.
        • Stauber R.
        • et al.
        Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment.
        J Hepatol. 2016; 65: 856-858
        • Cheung M.C.
        • Walker A.J.
        • Hudson B.E.
        • Verma S.
        • McLauchlan J.
        • Mutimer D.J.
        • et al.
        Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
        J Hepatol. 2016; 65: 741-747
        • Austin P.C.
        • Lee D.S.
        • Fine J.P.
        Introduction to the analysis of survival data in the presence of competing risks.
        Circulation. 2016; 133: 601-609
        • European Association for the Study of the Liver
        • European Organisation for Research and Treatment of Cancer
        EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2013; 56: 908-943